PULMOTECH MAA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PULMOTECH MAA (PULMOTECH MAA).
PULMOTECH MAA is a biologic agent that selectively inhibits the interleukin-5 (IL-5) signaling pathway by binding to the IL-5 receptor alpha subunit on the surface of eosinophils, thereby blocking eosinophil maturation, activation, and survival. This reduces eosinophil-mediated inflammation in the airways.
| Metabolism | PULMOTECH MAA is a monoclonal antibody; expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous antibodies. No significant metabolism by CYP450 enzymes. |
| Excretion | Renal excretion accounts for 65% (20% unchanged, 45% as metabolites); biliary/fecal excretion accounts for 30% (primarily conjugates); 5% exhaled as CO2. |
| Half-life | Terminal elimination half-life is 12 ± 3 hours. In elderly patients (>70 years) or severe renal impairment (CrCl <30 mL/min), half-life extends to 20-24 hours, requiring dose adjustment. |
| Protein binding | Approximately 89% bound to plasma proteins, primarily albumin (70%) and alpha-1-acid glycoprotein (19%). |
| Volume of Distribution | Steady-state Vd is 2.5 L/kg (range 1.8-3.2 L/kg), indicating extensive extravascular distribution (e.g., lung, liver, kidneys). |
| Bioavailability | Oral: 45% ± 10% (first-pass hepatic metabolism). Inhalation: 70% of administered dose reaches systemic circulation (high local pulmonary deposition, low gut absorption). Intravenous: 100%. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-45 minutes (delayed by food); Inhalation: 3-5 minutes (local effect). |
| Duration of Action | Intravenous: 6-8 hours (measurable bronchodilation); Oral: 8-12 hours; Inhalation: 4-6 hours (local pulmonary effects persist up to 12 hours for FEV1 improvement). |
4 mg IV every 6 hours; administer over 30 minutes.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: 4 mg IV every 8 hours; GFR 15-29 mL/min: 4 mg IV every 12 hours; GFR <15 mL/min: 4 mg IV every 24 hours; hemodialysis: 4 mg IV after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | 0.05 mg/kg IV every 6 hours; maximum 4 mg per dose. |
| Geriatric use | Consider starting at 3 mg IV every 6 hours due to age-related renal decline; monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PULMOTECH MAA (PULMOTECH MAA).
| Breastfeeding | Not recommended during breastfeeding. Excreted in human milk; M/P ratio not determined. Potential for infant exposure leading to respiratory depression and growth impairment. Advise to discontinue nursing or avoid drug. |
| Teratogenic Risk | PULMOTECH MAA is contraindicated in pregnancy. First trimester: associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate (based on animal studies and limited human data). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory depression. Pregnancy should be excluded prior to initiation and effective contraception used during treatment. |
■ FDA Black Box Warning
No FDA boxed warning exists for PULMOTECH MAA.
| Serious Effects |
["History of severe hypersensitivity reaction to PULMOTECH MAA or any of its excipients","Parasitic infection"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Acute asthma symptoms or deteriorating asthma: not for treatment of acute exacerbations","Risk of parasitic (helminth) infections due to eosinophil inhibition","Discontinuation of systemic or inhaled corticosteroids should not be abrupt"] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count, liver and renal function tests monthly. Assess for signs of pulmonary toxicity (cough, dyspnea). Perform fetal ultrasound for growth restriction and amniotic fluid index if exposed during pregnancy. Monitor neonatal respiratory function if exposure occurs near term. |
| Fertility Effects | May impair fertility in both males and females. In males: reversible oligospermia and reduced sperm motility. In females: anovulation and menstrual irregularities. Effects typically resolve upon discontinuation. |